CUE
CUE BIOPHARMA INC
$3.32
Earnings Summary
Net Profits | $-2.84Mn |
Highlights
CUE BIOPHARMA INC’s net profit fell -47.37% since last year same period to $-2.84Mn in the Q4 2016. On a quarterly growth basis, CUE BIOPHARMA INC has generated -40.43% fall in its net profits since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the CUE BIOPHARMA INC post its latest quarter earnings
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Current Year | -0.34 |
Highlights
CUE BIOPHARMA INC’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a 10.53% jump from last quarter’s estimates.
CUE BIOPHARMA INC’s earning per share (EPS) estimates for the current year stand at -0.34.
Key Ratios
Key ratios of the CUE BIOPHARMA INC post its Q4 2022 earnings
Return on Assets (ROA) | -0.37 |
Return on Equity (ROE) | -0.82 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CUE BIOPHARMA INC’s return on assets (ROA) stands at -0.37.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CUE BIOPHARMA INC’s return on equity (ROE) stands at -0.82.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2020-03-12 | -0.45 | -0.36 | 20% |
2019-05-08 | -0.4 | -0.54 | -35% |
2019-11-07 | -0.44 | -0.31 | 29.55% |
2019-08-08 | -0.56 | -0.46 | 17.86% |
Company Information
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.
Organisation | CUE BIOPHARMA INC |
Headquarters | 21 Erie Street, Cambridge, MA, United States, 02139 |
Employees | 0 |
Industry | Health Technology |
CEO | Daniel Passeri |
